Copper IUDs less likely to contribute to cervical cancer than hormonal IUDs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Patients who used copper intrauterine devices were found to have a lower risk of high-grade cervical neoplasms compared to users of the levonorgestrel-releasing intrauterine system, according to a Columbia study recently published in Obstetrics & Gynecology.

Studies from the 1980s suggested reduced risk of cervical cancer among women who used an intrauterine contraceptive, though those studies did not differentiate between the varying types of IUDs. Furthermore, much of the data from those studies was collected prior to the availability of most hormonal IUDs (LNG-IUS).

By standardizing four decades’ worth of data from the Columbia University Irving Medical Center database through the OMOP Common Data Model and using high-level analytics developed within the Observational Health Data Sciences and Informatics (OHDSI) collaboration, the research team ran a retrospective cohort analysis of more than 10,000 patients who received IUDs.

The diagnosis of high-grade cervical neoplasia was 0.7% in the Cu IUD cohort and 1.8% in the LNG-IUS cohort.

“Copper and hormonal IUDs may have different physiological effects on the female genitourinary system,” says Matthew Spotnitz, MD, MPH, a Postdoctoral Research Scientist within the Department of Biomedical Informatics and lead author of this study. “Consequently, the risk of cervical neoplasms may be different for copper and hormonal IUD users. Our findings may help patients and healthcare providers make informed decisions about whether the benefits of hormonal IUD use, compared to copper IUD use, are greater than the risks.”

Spotnitz noted that the research team hopes to lead a network study across other databases within the OHDSI network, which spans 19 countries, 133 unique databases converted to the OMOP CDM, and more than one billion patient records.

“The proportions of women who use copper and hormonal IUDs may vary among institutions,” Spotnitz says. “Overall, IUD use has become more popular over the past 20 years. Copper IUD use has remained constant whereas hormonal IUD use has increased. The rising popularity of hormonal IUDs may be related to the fact that they decrease the pain and bleeding of menses.”

The study notes that more than 100 million women use IUDs as contraception around the world, and these findings have implications for the larger population of current IUD users.

The full study is entitled “Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users.”

DBMI assistant professor Karthik Natarajan, PhD, DBMI adjunct professor Patrick Ryan, PhD, and Epidemiology, Population and Family Health professor Carolyn Westhoff, MD, collaborated on this study. Natarajan is also affiliated with the Columbia Data Science Institute.

OHDSI is an international, open-science collaborative that looks to improve health by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care.

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login